Compare Microsoft (MSFT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs ResMed Inc. — how do they compare? Microsoft trades at $498.96 (market cap $3.74T), while ResMed Inc. trades at $222.78 (market cap $32.61B). The key difference: Microsoft is far larger — about 114.7× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.17%). Which is the better fit depends on your goals.
| MSFT | RMD | |
|---|---|---|
Market Cap | $3.74T | $32.61B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $293.73 |
52-Week Low | $352.83 | $182.82 |
Enterprise Value | $3.72T | $31.97B |
Dividend Yield | 0.72% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $506.06, up 1.21% with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with $281.72B revenue, 40.31% net margin, and consistent earnings beats. Recent news highlights Microsoft's AI leadership and Azure growth potential, though concerns about capital expenditures persist. The stock trades near pivot point resistance at $507 with strong support at $500.
Outlook remains positive with 80% analyst buy ratings and $552.73 consensus target offering 9% upside. Key opportunities include AI integration and cloud growth, while risks involve competitive pressures and execution on large capital investments. The combination of strong fundamentals and technical momentum supports a constructive view for investors.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
